[96a5a0]: / output / allTrials / identified / NCT00006220_identified.json

Download this file

542 lines (542 with data), 27.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
{
"info": {
"nct_id": "NCT00006220",
"official_title": "Arsenic Trioxide Alone or With ATRA (Vesanoid) for Resistant Hematologic Malignancy",
"inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 15 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Patients with any of the following diagnoses: Acute lymphocytic leukemia OR acute myeloid leukemia Failed to achieve complete remission (CR) with induction chemotherapy OR Relapsed within one year of initial CR OR Relapsed after autologous or allogeneic transplant OR Any subsequent relapse OR Refractory following relapse CR2 or more (phase I only) Blastic phase chronic myelogenous leukemia Prior therapy allowed Myelodysplastic syndrome, including the following: Refractory anemia with excess blasts (RAEB) OR RAEB in transformation (high intermediate or high risk only) Relapsed after transplant CR2 or more (phase I only) Non-Hodgkin's lymphoma OR Hodgkin's disease Newly diagnosed or in first relapse and failed to achieve CR or partial remission after induction or salvage chemotherapy OR Second or later relapse OR Relapsed after transplant No disease that can be encompassed in a standard radiation port No asymptomatic, minimally symptomatic, or low grade lymphoma Multiple myeloma Symptomatic, progressive, or recurrent disease after treatment with alkylating agents, high dose corticosteroids, or anthracyclines OR Relapsed following transplant Not eligible for autologous or allogeneic transplant A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol uses the former terminology.\n\nPATIENT CHARACTERISTICS: Age: 15 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 500/mm3* Platelet count at least 50,000/mm3* *Unless caused by marrow infiltration by tumor No congenital bleeding disorder Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT less than 3 times ULN Renal: Creatinine clearance greater than 25 mL/min Cardiovascular: No myocardial infarction, stroke, or unstable angina within the past 12 months No uncompensated congestive heart failure Left ventricular ejection fraction at least 40% Other: No active infection HIV negative HTLV I/II negative Not pregnant Fertile patients must use effective contraception during and for 2 years following study\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Prior hydroxyurea allowed Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics Surgery: Not specified Other: At least 3 weeks since prior antileukemic therapy (except leukapheresis)"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 15 Years",
"criterions": [
{
"exact_snippets": "minimum age of 15 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "DISEASE CHARACTERISTICS: Patients with any of the following diagnoses: Acute lymphocytic leukemia OR acute myeloid leukemia Failed to achieve complete remission (CR) with induction chemotherapy OR Relapsed within one year of initial CR OR Relapsed after autologous or allogeneic transplant OR Any subsequent relapse OR Refractory following relapse CR2 or more (phase I only) Blastic phase chronic myelogenous leukemia Prior therapy allowed Myelodysplastic syndrome, including the following: Refractory anemia with excess blasts (RAEB) OR RAEB in transformation (high intermediate or high risk only) Relapsed after transplant CR2 or more (phase I only) Non-Hodgkin's lymphoma OR Hodgkin's disease Newly diagnosed or in first relapse and failed to achieve CR or partial remission after induction or salvage chemotherapy OR Second or later relapse OR Relapsed after transplant No disease that can be encompassed in a standard radiation port No asymptomatic, minimally symptomatic, or low grade lymphoma Multiple myeloma Symptomatic, progressive, or recurrent disease after treatment with alkylating agents, high dose corticosteroids, or anthracyclines OR Relapsed following transplant Not eligible for autologous or allogeneic transplant A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol uses the former terminology.",
"criterions": [
{
"exact_snippets": "Acute lymphocytic leukemia",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Acute lymphocytic leukemia"
}
]
},
{
"exact_snippets": "acute myeloid leukemia",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "acute myeloid leukemia"
}
]
},
{
"exact_snippets": "Failed to achieve complete remission (CR) with induction chemotherapy",
"criterion": "remission status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "Failed to achieve complete remission with induction chemotherapy"
}
]
},
{
"exact_snippets": "Relapsed within one year of initial CR",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "time since CR",
"expected_value": "within one year"
}
]
},
{
"exact_snippets": "Relapsed after autologous or allogeneic transplant",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "post-transplant",
"expected_value": true
}
]
},
{
"exact_snippets": "Any subsequent relapse",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "subsequent relapse",
"expected_value": true
}
]
},
{
"exact_snippets": "Refractory following relapse CR2 or more (phase I only)",
"criterion": "refractory status",
"requirements": [
{
"requirement_type": "following relapse CR2 or more",
"expected_value": true
}
]
},
{
"exact_snippets": "Blastic phase chronic myelogenous leukemia",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Blastic phase chronic myelogenous leukemia"
}
]
},
{
"exact_snippets": "Myelodysplastic syndrome",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Myelodysplastic syndrome"
}
]
},
{
"exact_snippets": "Refractory anemia with excess blasts (RAEB)",
"criterion": "subtype of myelodysplastic syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Refractory anemia with excess blasts (RAEB)"
}
]
},
{
"exact_snippets": "RAEB in transformation (high intermediate or high risk only)",
"criterion": "subtype of myelodysplastic syndrome",
"requirements": [
{
"requirement_type": "risk level",
"expected_value": [
"high intermediate",
"high"
]
}
]
},
{
"exact_snippets": "Relapsed after transplant CR2 or more (phase I only)",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "post-transplant",
"expected_value": true
}
]
},
{
"exact_snippets": "Non-Hodgkin's lymphoma",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Non-Hodgkin's lymphoma"
}
]
},
{
"exact_snippets": "Hodgkin's disease",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Hodgkin's disease"
}
]
},
{
"exact_snippets": "Newly diagnosed or in first relapse and failed to achieve CR or partial remission after induction or salvage chemotherapy",
"criterion": "remission status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "Newly diagnosed or in first relapse and failed to achieve CR or partial remission after induction or salvage chemotherapy"
}
]
},
{
"exact_snippets": "Second or later relapse",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "relapse count",
"expected_value": "Second or later"
}
]
},
{
"exact_snippets": "Relapsed after transplant",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "post-transplant",
"expected_value": true
}
]
},
{
"exact_snippets": "No disease that can be encompassed in a standard radiation port",
"criterion": "disease location",
"requirements": [
{
"requirement_type": "radiation port",
"expected_value": "cannot be encompassed"
}
]
},
{
"exact_snippets": "No asymptomatic, minimally symptomatic, or low grade lymphoma",
"criterion": "lymphoma grade",
"requirements": [
{
"requirement_type": "symptom presence",
"expected_value": "not asymptomatic, minimally symptomatic, or low grade"
}
]
},
{
"exact_snippets": "Multiple myeloma",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "Multiple myeloma"
}
]
},
{
"exact_snippets": "Symptomatic, progressive, or recurrent disease after treatment with alkylating agents, high dose corticosteroids, or anthracyclines",
"criterion": "disease status",
"requirements": [
{
"requirement_type": "treatment response",
"expected_value": "Symptomatic, progressive, or recurrent after treatment with alkylating agents, high dose corticosteroids, or anthracyclines"
}
]
},
{
"exact_snippets": "Relapsed following transplant",
"criterion": "relapse status",
"requirements": [
{
"requirement_type": "post-transplant",
"expected_value": true
}
]
},
{
"exact_snippets": "Not eligible for autologous or allogeneic transplant",
"criterion": "transplant eligibility",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": false
}
]
}
]
},
{
"line": "PATIENT CHARACTERISTICS: Age: 15 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 500/mm3* Platelet count at least 50,000/mm3* *Unless caused by marrow infiltration by tumor No congenital bleeding disorder Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT less than 3 times ULN Renal: Creatinine clearance greater than 25 mL/min Cardiovascular: No myocardial infarction, stroke, or unstable angina within the past 12 months No uncompensated congestive heart failure Left ventricular ejection fraction at least 40% Other: No active infection HIV negative HTLV I/II negative Not pregnant Fertile patients must use effective contraception during and for 2 years following study",
"criterions": [
{
"exact_snippets": "Age: 15 and over",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": true
},
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "years"
}
}
]
},
{
"exact_snippets": "Performance status: ECOG 0-2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": "ECOG"
},
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "Life expectancy: Not specified",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "specification",
"expected_value": "Not specified"
}
]
},
{
"exact_snippets": "Absolute neutrophil count at least 500/mm3",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "minimum count",
"expected_value": {
"operator": ">=",
"value": 500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Platelet count at least 50,000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "minimum count",
"expected_value": {
"operator": ">=",
"value": 50000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "No congenital bleeding disorder",
"criterion": "congenital bleeding disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Bilirubin less than 2 times upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "maximum level",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "SGOT less than 3 times ULN",
"criterion": "SGOT level",
"requirements": [
{
"requirement_type": "maximum level",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Creatinine clearance greater than 25 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "minimum clearance",
"expected_value": {
"operator": ">",
"value": 25,
"unit": "mL/min"
}
}
]
},
{
"exact_snippets": "No myocardial infarction, stroke, or unstable angina within the past 12 months",
"criterion": "myocardial infarction, stroke, or unstable angina",
"requirements": [
{
"requirement_type": "occurrence within past 12 months",
"expected_value": false
}
]
},
{
"exact_snippets": "No uncompensated congestive heart failure",
"criterion": "uncompensated congestive heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Left ventricular ejection fraction at least 40%",
"criterion": "left ventricular ejection fraction",
"requirements": [
{
"requirement_type": "minimum fraction",
"expected_value": {
"operator": ">=",
"value": 40,
"unit": "%"
}
}
]
},
{
"exact_snippets": "No active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "HIV negative",
"criterion": "HIV status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "HTLV I/II negative",
"criterion": "HTLV I/II status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "not pregnant"
}
]
},
{
"exact_snippets": "Fertile patients must use effective contraception during and for 2 years following study",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "requirement for fertile patients",
"expected_value": "must use effective contraception during and for 2 years following study"
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Prior hydroxyurea allowed Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics Surgery: Not specified Other: At least 3 weeks since prior antileukemic therapy (except leukapheresis)",
"criterions": [
{
"exact_snippets": "Prior hydroxyurea allowed",
"criterion": "prior hydroxyurea",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"exact_snippets": "At least 3 weeks since prior antileukemic therapy (except leukapheresis)",
"criterion": "prior antileukemic therapy",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}